Epidemiology, survival, and costs of localized gastrointestinal stromal tumors

International Journal of General Medicine

Volumn 4, Issue , 2011, Pages 121-130

  Rubin, Jaime L ^a   Sanon, Myrlene ^a   Taylor, Douglas C A ^a   Coombs, John ^b   Bollu, Vamsi ^b   Sirulnik, Leonardo ^b  

^a i3 Global   (Canada)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Burden of illness; Cancer; GIST

Indexed keywords

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER REGISTRY; CANCER RISK; CANCER SURGERY; CHILD; CONTROLLED STUDY; COST OF ILLNESS; DISEASE DURATION; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRESCHOOL CHILD; SEX DIFFERENCE; SURVIVAL RATE; TUMOR LOCALIZATION; TUMOR RECURRENCE;

EID: 84897364908     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: 10.2147/IJGM.S16090     Document Type: Article

References (19)

1. D'Amato G, Steinert DM, McAuliffe JC, Trent JC. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control. 2005;12(1):44-56.
2. Gold JS, DeMatteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg. 2006;244(2): 176-184.
3. Van der Zwan SM, DeMatteo RP. Gastrointestinal stromal tumor: 5 years later. Cancer. 2005;104(9):1781-1788.
4. Demetri GD. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Eur J Cancer. 2002;38 Suppl 5: S52-S59.
5. NCCN.org [homepage on the Internet]. The NCCN Clinical Practice Guidelines in Oncology™ Soft Tissue Carcinoma (Version I.2009). ©2009 National Comprehensive Cancer Network, Inc. Available from: http://www.NCCN.org. Accessed May 5, 2009.
6. Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg. 1992;215(1):68-77.
7. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231(1): 51-58.
8. Shiu MH, Farr GH, Papachristou DN, Hajdu SI. Myosarcomas of the stomach: natural history, prognostic factors and management. Cancer. 1982;49(1):177-187.
9. DeMatteo RP, Gold JS, Saran L, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer. 2008;112(3):608-615.
10. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer. 2005;103(4):821-829.
11. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130(10):1466-1478.
12. Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol. 2005;100(1):162-168.
13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
14. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
15. Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data. Biometrics. 1997;53(2):419-434.
16. Martin J, Poveda A, Llombart-Bosch A, et al. Spanish Group for Sarcoma Research. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol. 2005;23(25):6190-6198.
17. Stokes M, Thompson D, Montoya E, Weinstein MC, Winer EP, Earle CC. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. Value Health. 2008;11(2): 213-220.
18. Howe JR, Karnell LH, Scott-Conner C. Small bowel sarcoma: analysis of survival from the National Cancer Data Base. Ann Surg Oncol. 2001; 8(6):496-508.
19. Frey CM, McMillen MM, Cowan CD, Horm JW, Kessler LG. Representativeness of the surveillance, epidemiology, and end results program data: recent trends in cancer mortality rates. J Natl Cancer Inst. 1992;84(11):872-877.